

## Supplementary material

*Rusin G, Ząbczyk M, Natorska J, et al. Direct oral anticoagulants in patients with atrial fibrillation and liver cirrhosis: a single-center experience. Kardiol Pol. 2021.*

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Baseline characteristics and follow-up of the patients according to the Child-Pugh class

	All (n = 42)	Child-Pugh A (n = 23)	Child-Pugh B (n = 19)	P value
Age, years	65.4 (7.0)	66.0 (6.9)	64.7 (7.2)	0.60
Male sex, n (%)	17 (40.5)	10 (43.5)	7 (36.8)	0.70
Body mass index, kg/m <sup>2</sup>	27.8 (4.3)	27.7 (4.2)	27.8 (4.4)	0.90
Current smoking, n (%)	9 (21.4)	2 (8.7)	7 (36.8)	0.024
Type of atrial fibrillation, n (%)				0.30
Paroxysmal	28 (66.7)	17 (73.9)	11 (57.9)	
Persistent	7 (16.7)	4 (17.4)	3 (15.8)	
Permanent	7 (16.7)	2 (8.7)	5 (26.3)	
HAS-BLED score	2.5 (2.0–4.0)	2.5 (2.0–4.0)	3.0 (2.0–3.0)	0.30
CHA2DS2-VASc score	2.0 (1.0–3.0)	2.0 (1.0–3.0)	2.0 (1.0–4.0)	0.64

<b>Cause of liver cirrhosis, n (%)</b>				0.16
Viral hepatitis	12 (28.6)	7 (30.4)	5 (26.3)	
Alcohol	15 (35.7)	11 (47.8)	4 (21.1)	
Other	15 (35.7)	5 (21.7)	10 (52.6)	
<b>Invasive therapy of esophageal varices, n (%)</b>	22 (52.4)	13 (56.5)	9 (47.4)	0.60
<b>INR &gt;1.2, n (%)</b>	22 (52.4)	11 (47.3)	11 (57.9)	0.55
<b>Platelet count &lt;100 000/<math>\mu</math>L, n (%)</b>	14 (31.0)	6 (26.1)	8 (42.1)	0.34
<b>Serum albumin &lt;35 g/L, n (%)</b>	19 (45.2)	3 (13.0)	16 (84.2)	<0.001
<b>Comorbidities, n (%)</b>				
Hypertension	12 (28.6)	(30.4)	5 (26.3)	0.80
Diabetes mellitus	2 (4.8)	2 (8.7)	0 (0.0)	0.11
Hyperlipidemia	19 (45.2)	10 (43.5)	9 (47.4)	0.80
Heart failure	14 (33.3)	10 (43.5)	4 (21.1)	0.12
Previous myocardial infarction	3 (7.1)	1 (4.3)	2 (10.5)	0.44
History of bleeding	8 (19.1)	6 (26.1)	2 (10.5)	0.19
<b>Medications, n (%)</b>				
Antiplatelet drug	6 (14.3)	4 (17.4)	2 (10.5)	0.52
Statin	6 (14.3)	1 (4.3)	5 (26.3)	0.038
ACEi	11 (26.2)	7 (30.4)	4 (21.1)	0.49

$\beta$ -blocker	33 (78.6)	17 (73.9)	16 (84.2)	0.41
PPI	33 (78.6)	19 (82.6)	14 (73.7)	0.48
<b>Follow-up, n (%)</b>				
Stroke/TIA	2 (4.8)	0 (0.0)	2 (10.5)	0.20
Systemic embolism	2 (4.8)	2 (8.7)	0 (0.0)	0.29
Major bleeding	3 (7.1)	1 (4.3)	2 (10.5)	0.43
CRNMB	5 (11.9)	3 (13.0)	2 (10.5)	0.59
Death	10 (23.8)	3 (13.0)	7 (36.8)	0.08

Values are n (%), mean (standard deviation), or median (interquartile range). ACEi, angiotensin converting enzyme inhibitor; CHA<sub>2</sub>DS<sub>2</sub>-VASc, congestive heart failure, hypertension, age  $\geq 75$  years, diabetes, stroke/transient ischemic attack/thromboembolism, vascular disease, age 65–75 years, sex category;

Abbreviations: CRNMB, clinically relevant non-major bleeding; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly; INR, international normalized ratio; PPI, proton pump inhibitors; TIA, transient ischemic attack

Table S2. Baseline characteristics of the patients according to the type of direct oral anticoagulant

	<b>All (n = 42)</b>	<b>Apixaban (n = 14)</b>	<b>Rivaroxaban (n = 17)</b>	<b>Dabigatran (n = 11)</b>	<i>P</i> value
<b>Age, years</b>	65.4 (7.0)	69.4 (7.0)	65.3 (5.5)	60.6 (6.4)	0.005
<b>Male sex, n (%)</b>	17 (40.5)	7 (50.0)	7 (41.2)	3 (27.3)	0.51

<b>Body mass index,</b> <b>kg/m<sup>2</sup></b>	27.8 (4.3)	27.9 (4.6)	26.7 (3.0)	29.3 (5.3)	0.27
<b>Current smoking,</b> <b>n (%)</b>	9 (21.4)	6 (42.9)	1 (5.9)	2 (18.2)	0.053
<b>Type of atrial</b> <b>fibrillation, n (%)</b>					0.76
Paroxysmal	28 (66.7)	8 (57.1)	12 (70.6)	8 (72.7)	
Persistent	7 (16.7)	2 (14.3)	3 (17.6)	2 (18.2)	
Permanent	7 (16.7)	4 (28.6)	2 (11.8)	1 (9.1)	
<b>HAS-BLED score</b>	2.5 (2.0– 4.0)	2.5 (2.0– 4.0)	3.0 (2.0–3.0)	2.0 (2.0–4.0)	0.99
<b>CHA2DS2-VASc</b> <b>score</b>	2.0 (1.0– 3.0)	2.5 (1.75– 4)	2.0 (1.0–2.5)	2.0 (2.0–3.0)	0.39
<b>Cause of liver</b> <b>cirrhosis, n (%)</b>					0.008
Viral hepatitis	12 (28.6)	5 (35.7)	4 (23.5)	3 (27.3)	
Alcohol	15 (35.7)	1 (7.1)	10 (58.8)	4 (36.4)	
Other	15 (35.7)	8 (57.1)	3 (17.6)	4 (36.4)	
<b>Invasive therapy of</b> <b>esophageal varices,</b> <b>n (%)</b>	22 (52.4)	6 (42.9)	7 (41.2)	9 (81.8)	0.07
<b>INR &gt;1.2, n (%)</b>	22 (52.4)	9 (64.3)	6 (35.3)	7 (63.6)	0.19
<b>Platelet count &lt;100</b> <b>000/μL, n (%)</b>	14 (31.0)	4 (28.6)	5 (29.4)	5 (45.5)	0.61

<b>Serum albumin</b>	19 (45.2)	8 (57.1)	6 (35.3)	5 (45.5)	0.48
<b>&lt;35 g/L, n (%)</b>					
<b>Child-Pugh Class,</b>					0.21
<b>n (%)</b>					
A	23 (54.8)	5 (35.7)	11 (64.7)	7 (63.6)	
B	19 (45.2)	9 (64.3)	6 (35.3)	4 (36.4)	
<b>Comorbidities, n (%)</b>					
Hypertension	12 (28.6)	4 (28.6)	4 (23.5)	4 (36.4)	0.90
Diabetes mellitus	2 (4.8)	1 (7.1)	0 (0.0)	1 (9.1)	0.51
Hyperlipidemia	19 (45.2)	8 (57.1)	7 (41.2)	4 (36.4)	0.53
Heart failure	14 (33.3)	1 (7.1)	8 (47.1)	5 (45.5)	0.032
Previous myocardial infarction	3 (7.1)	2 (14.3)	1 (5.9)	0 (0.0)	0.59
Peripheral artery disease	5 (11.9)	1 (7.1)	2 (11.8)	2 (18.2)	0.83
Chronic obstructive pulmonary disease	9 (21.4)	4 (28.6)	3 (17.6)	2 (18.2)	0.81
History of bleeding	8 (19.1)	2 (14.3)	3 (17.6)	3 (27.3)	0.78
<b>Medications, n (%)</b>					
Antiplatelet drug	6 (14.3)	3 (21.4)	1 (5.9)	2 (18.2)	0.49
Statin	6 (14.3)	4 (28.6)	2 (11.8)	0 (0.0)	0.17
ACEi	11 (26.2)	3 (21.4)	4 (23.5)	4 (36.4)	0.75
$\beta$ -blocker	33 (78.6)	12 (85.7)	14 (82.4)	7 (63.6)	0.40
PPI	33 (78.6)	14 (100)	12 (70.6)	7 (63.6)	0.034

---

Values are n (%), mean (standard deviation), or median (interquartile range).

Abbreviations: ACEi, angiotensin converting enzyme inhibitor; CHA<sub>2</sub>DS<sub>2</sub>-VASc, congestive heart failure, hypertension, age  $\geq 75$  years, diabetes, stroke/transient ischemic attack/thromboembolism, vascular disease, age 65–75 years, sex category; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly; INR, international normalized ratio; PPI, proton pump inhibitors; TIA, transient ischemic attack

---